InVivo Therapeutics

Recommendations

Info

Financial Information Trading Symbol NVIV Stock Price 1 $7.00 Exchange Market Cap 1 Primary Shares Outstanding 2 Fully Diluted Shares 2 NASDAQ $191.5 M 27.0 M 30.7 M Avg. Daily Trading Volume (3 mo) 1 290,365 Cash on Hand 2 $22.1 M • Financings in May 2014 and Jan 2015 resulted in net proceeds of $14.6 M and $11.0 M, respectively • Established $50 M ATM with Cowen • Q1-Q3 2015 warrant and stock option exercises resulted in net proceeds of $8.8 M • Monthly cash burn of about $1.2 M InVivo Therapeutics 1 As of 1/6/16 2 As of 9/30/15 4
2014 – 2015 Corporate Accomplishments 1. Experienced leadership team in place 2. Raised cash to fund 2015-2016 operations 3. Accelerated Neuro-Spinal Scaffold development program 4. Implanted 5 patients with the Neuro-Spinal Scaffold in the pilot study 5. Announced promising clinical results 6. Converted pilot study to INSPIRE study – a pivotal study for marketing application 7. Announced Bioengineered Neural Trails program for chronic SCI 8. Dramatically strengthened and broadened intellectual property portfolio 9. Major increase in publications and presentations at scientific meetings 10. Uplisted to NASDAQ InVivo Therapeutics 5
Page 1 and 2: InVivo Therapeutics Developing Inno
Page 3: Company Overview • Publicly trade
Page 7 and 8: Spinal Cord Injury: A Huge Unmet Cl
Page 9 and 10: Neuro-Spinal Scaffold for Acute SCI
Page 11 and 12: Progression of Acute SCI to Post-Tr
Page 13 and 14: Acute Cavitation Within the Spinal
Page 15 and 16: Neuro-Spinal Scaffold Provides Stru
Page 17 and 18: The Neuro-Spinal Scaffold Facilitat
Page 19 and 20: Neuro-Spinal Scaffold Increases Fun
Page 21 and 22: The Neuro-Spinal Scaffold Improved
Page 23 and 24: Neuro-Spinal Scaffold for Acute SCI
Page 25 and 26: The INSPIRE Study InVivo Study of P
Page 27 and 28: Clinical Sites • Banner Universit
Page 29 and 30: Marked Functional Improvement in Fi
Page 31 and 32: Future Clinical Development Strateg
Page 33 and 34: Chronic Spinal Cord Injury: An Enor
Page 35 and 36: I. Novel Surgical Approach: Minimal
Page 37 and 38: Trail Injection Provides Many Advan
Page 39 and 40: Neurosurgeons Successfully Test the
Page 41 and 42: MRI Demonstrates a Longitudinal Tra
Page 43 and 44: III. Neural Stem Cells Create a Bio
Page 45 and 46: Next Steps for Bioengineered Neural
Page 47 and 48: Neuro-Spinal Scaffold and Bioengine
Page 49 and 50: Increased Publications and Presenta
Page 51: Upcoming Anticipated Milestones •

InVivo Therapeutics

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?